Drug Eluting Balloons

Drug Eluting Balloons Market Outlook

The global Drug Eluting Balloons Market is projected to reach approximately USD 3.8 billion by 2035, growing at a CAGR of around 6.5% from 2025 to 2035. One of the critical growth factors driving this market is the increasing prevalence of cardiovascular diseases, which has led to an upsurge in demand for innovative and effective treatment options. Additionally, the rising geriatric population, who are more susceptible to vascular diseases, significantly contributes to the market growth. The advent of technology in developing advanced drug eluting balloons that provide localized drug delivery is enhancing procedural efficacy, further propelling market expansion. Moreover, increased awareness regarding the benefits of drug-eluting therapies over traditional angioplasty is anticipated to foster growth, making this an attractive sector for investment.

Growth Factor of the Market

The Drug Eluting Balloons Market is witnessing remarkable growth driven by several pivotal factors. The surge in the prevalence of chronic diseases such as coronary artery disease and peripheral artery disease is one of the primary catalysts for market expansion. Furthermore, advancements in healthcare infrastructure and technology have led to improved patient outcomes and greater accessibility to treatment options. The growing focus on minimally invasive surgical procedures is also shaping market dynamics, as drug eluting balloons offer less trauma and quicker recovery times compared to traditional methods. Additionally, the continuous research and development activities to enhance the effectiveness and safety profiles of these devices contribute to market growth. As countries continue to invest in healthcare and facilitate faster regulatory approvals, the market is poised for sustained growth in the coming years.

Key Highlights of the Market

• The global Drug Eluting Balloons Market is expected to reach USD 3.8 billion by 2035, with a CAGR of 6.5%.
• Increasing incidence of cardiovascular and peripheral vascular diseases is significantly driving market demand.
• Technological advancements in drug delivery systems are enhancing treatment efficacy and patient outcomes.
• The shift towards minimally invasive procedures is favoring the adoption of drug eluting balloons.
• Emerging markets are providing lucrative opportunities for growth due to rising healthcare expenditures.

By Product Type

Coronary Drug Eluting Balloons:

Coronary drug eluting balloons (DEBs) are specifically designed for treating coronary artery disease by delivering therapeutic agents directly to the targeted site. These balloons have gained popularity due to their ability to reduce restenosis rates and improve patient outcomes. The coronary segment is expected to witness significant growth owing to the high prevalence of atherosclerotic disease globally. Technological advancements that enhance the performance of these balloons, such as better drug formulas and delivery mechanisms, further enhance their adoption. Increasing efforts by manufacturers to develop superior products that minimize complications during procedures are also contributing to the growth in this segment.

Peripheral Drug Eluting Balloons:

Peripheral drug eluting balloons are utilized for treating peripheral artery disease (PAD), a condition that affects blood flow in limbs. The demand for peripheral DEBs is surging due to the rising incidence of PAD, especially among the aging population. These balloons are particularly effective in complex lesions, where conventional therapies may fall short. The ongoing research aimed at improving the drug formulations and coating technologies is likely to further drive the market for peripheral DEBs. Furthermore, the increasing awareness about the benefits of localized drug delivery in managing peripheral vascular conditions is supporting the growth of this product type.

Urology Drug Eluting Balloons:

Urology drug eluting balloons are designed for various urological applications, particularly in treating conditions like bladder cancer and recurrent urinary tract infections. The growth in this segment is primarily attributed to the increasing incidence of urological disorders, which necessitate innovative treatment solutions. Urology DEBs allow for specific drug delivery, minimizing systemic side effects and enhancing therapeutic efficacy. As ongoing clinical studies continue to validate the benefits of these devices, the urology segment is likely to see expanded adoption and growth in the coming years. Moreover, advancements in balloon technology are leading to increased functionality and safety, making them a viable option for urological treatments.

Neurology Drug Eluting Balloons:

Neurology drug eluting balloons are emerging as a promising treatment modality for various neurological disorders, including neurovascular diseases. The application of DEBs in neurology represents a significant shift towards targeted therapies that can reduce complications associated with systemic drug administration. The anticipated growth in this segment can be credited to the increasing prevalence of neurological disorders and the demand for innovative treatment options. As advancements in neuro balloon technology continue to evolve, the efficacy and safety of these devices are expected to improve, driving their adoption in clinical settings. Research studies focusing on the integration of drug coatings for localized drug release further solidify their potential in neurological applications.

Others:

This category includes drug eluting balloons designed for various other applications beyond the primary segments listed above. The growth in this sub-segment is fueled by ongoing innovations and research aimed at expanding the application range of drug eluting balloons. While these products may currently have a smaller market share compared to the other categories, they hold significant potential for future growth as healthcare providers seek novel solutions for specific medical challenges. This segment is expected to attract attention as more data becomes available demonstrating the effectiveness of DEBs in various other therapeutic areas.

By Application

Coronary Artery Disease:

The application of drug eluting balloons in treating coronary artery disease is a rapidly growing segment within the market. Coronary artery disease is one of the leading causes of morbidity and mortality worldwide, creating a high demand for effective treatment options. Drug eluting balloons significantly reduce the rates of restenosis compared to traditional balloon angioplasty. As more healthcare providers adopt these devices, the market for coronary artery disease applications is expected to grow substantially. Furthermore, clinical studies demonstrating the long-term benefits of DEBs in this application are paving the way for broader acceptance among cardiovascular specialists.

Peripheral Artery Disease:

The application of drug-eluting balloons in peripheral artery disease (PAD) management is gaining traction as the prevalence of PAD continues to rise globally. These balloons are particularly effective in treating lesions in the femoral-popliteal artery, which has historically posed treatment challenges. The significant advantages of drug eluting balloons, such as lower rates of restenosis and improved patient outcomes, are driving their adoption in clinical practice. Additionally, the increasing number of clinical trials and positive outcomes related to DEBs in PAD treatments are likely to bolster market growth. As healthcare providers become more aware of the benefits of these devices, the adoption across this application is anticipated to accelerate.

Urological Diseases:

In the realm of urological diseases, drug eluting balloons are becoming a transformative option for various conditions, notably bladder cancer and recurrent urinary tract infections. The unique ability of these balloons to deliver targeted therapies directly to the affected area is a major advantage, reducing systemic side effects. The application of DEBs in urology is particularly appealing given the need for precise and effective treatments. As more research supports the efficacy of drug eluting balloons in this domain, adoption rates are expected to increase significantly. The growing incidence of urological conditions also ensures a steady demand for innovative treatment options, further propelling this application segment.

Neurological Diseases:

Drug eluting balloons are emerging as a novel approach to treating various neurological diseases, particularly in neurovascular conditions. The targeted delivery of therapeutics through DEBs can potentially offer substantial benefits, such as reduced systemic exposure and enhanced localized effects. The growing interest in this application is driven by the increasing prevalence of neurological disorders, where traditional treatment options may not be as effective. Ongoing advancements in balloon technologies and drug formulations are likely to enhance their effectiveness in treating neurological diseases. As clinical understanding deepens regarding their applications, the market for DEBs in neurology is poised for significant growth.

Others:

The "Others" category encompasses miscellaneous applications for drug eluting balloons that do not fall explicitly within the primary categories discussed. Innovations in device technology and drug formulations are enabling manufacturers to explore additional applications, thereby broadening the utility of DEBs beyond the conventional uses. As research continues to unveil the potential effectiveness of drug eluting balloons in various medical conditions, this segment is anticipated to develop further. The flexibility and adaptability of drug eluting balloons in targeting specific therapeutic areas underlines their importance in the evolving landscape of medical treatments.

By Distribution Channel

Hospitals:

Hospitals remain the primary distribution channel for drug eluting balloons, accounting for a significant share of the market. The high demand for advanced medical devices within inpatient settings is driven by the need for effective treatment of critical conditions such as coronary and peripheral artery diseases. Hospitals possess the necessary infrastructure and resources to administer highly specialized procedures, making them key players in the DEB market. Moreover, the increasing number of cardiac and vascular surgeries conducted globally further solidifies this distribution channel's dominance. As hospitals continue to adopt innovative technologies to improve patient outcomes, the demand for drug eluting balloons is expected to grow correspondingly.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming an increasingly popular distribution channel for drug eluting balloons due to the shift towards outpatient procedures. These centers provide an efficient and cost-effective alternative to traditional hospital settings, allowing for shorter patient recovery times. The growth of ASCs in the drug eluting balloons market is driven by the rising demand for minimally invasive procedures, which is a key factor in enhancing patient satisfaction. Furthermore, ASCs are more flexible in terms of adopting new technologies, allowing for quicker integration of innovative drug eluting balloon therapies. As patient preferences shift towards outpatient services, the importance of ASCs in this market is expected to rise.

Specialty Clinics:

Specialty clinics play a crucial role in the distribution of drug eluting balloons, particularly for targeted treatments in specific medical fields such as cardiology and urology. These clinics are dedicated to providing specialized care, and their focus on specific patient populations ensures a tailored approach to treatment. The increasing number of specialty clinics across the globe is contributing to the expansion of drug eluting balloon applications, as they often employ the latest technologies and therapies. As collaboration between specialty clinics and device manufacturers enhances, the accessibility of drug eluting balloons is expected to improve, driving market growth. Additionally, the expertise offered by specialized personnel in these clinics further fosters confidence in the use of DEBs among patients.

Others:

The "Others" category encompasses various additional distribution channels for drug eluting balloons that do not fall under the primary categories of hospitals, ASCs, or specialty clinics. This may include online platforms, medical supply distributors, and other healthcare facilities that facilitate the distribution of advanced medical devices. The diversification of distribution channels is expected to contribute positively to market growth, as it enhances accessibility and availability of drug eluting balloons. As the healthcare landscape continues to evolve, the utilization of alternative channels is anticipated to expand, thus ensuring that patients and healthcare providers have increased options in sourcing these innovative devices.

By Drug Type

Paclitaxel-Coated Balloons:

Paclitaxel-coated balloons are among the most widely used drug eluting balloons, primarily utilized in the treatment of coronary and peripheral artery diseases. Paclitaxel, a chemotherapeutic agent, inhibits cell proliferation, thereby reducing the risk of restenosis following angioplasty procedures. The growing body of clinical evidence supporting the efficacy of paclitaxel-coated balloons continues to drive their market share. Furthermore, the ongoing research into optimizing drug delivery mechanisms and improving the coating techniques is likely to enhance the performance of these balloons. As a result, paclitaxel-coated balloons are expected to maintain their prominence in the market for drug eluting balloons.

Sirolimus-Coated Balloons:

Sirolimus-coated balloons are another significant product type within the drug eluting balloon market, known for their effectiveness in reducing restenosis rates. Sirolimus acts as an immunosuppressant, preventing excessive cell growth at the treatment site. The unique properties of sirolimus make it particularly valuable for use in vascular interventions, where managing tissue response is critical. The increasing adoption of sirolimus-coated balloons in clinical practice is attributed to their favorable safety and efficacy profiles. With ongoing clinical trials and studies investigating their applications in various vascular conditions, the demand for sirolimus-coated balloons is expected to rise in the coming years.

Other Drug Types:

The "Other Drug Types" category includes various drug formulations used in conjunction with drug eluting balloons that do not fall under the primary categories of paclitaxel or sirolimus. These may include novel agents currently being researched and developed to enhance the effectiveness of balloon angioplasty. The continuous innovation in drug formulations presents opportunities for manufacturers to differentiate their products and capture market share. As more data emerges regarding the potential benefits of alternative drug types, this segment is anticipated to witness growth. The focus on personalized medicine and targeted therapy is likely to play a significant role in driving the adoption of other drug types within the drug eluting balloons market.

By Region

The Drug Eluting Balloons Market demonstrates varied growth prospects across different regions, influenced by factors such as healthcare infrastructure, prevalence of diseases, and market dynamics. North America is currently one of the largest markets for drug eluting balloons, expected to account for over 40% of the global market share by 2035. The presence of advanced healthcare facilities, high disposable incomes, and a rising number of cardiovascular procedures are driving demand in this region. Furthermore, ongoing research initiatives and strong regulatory frameworks support market growth, projected to achieve a CAGR of 7% during the forecast period. The increasing emphasis on innovative treatment options and patient-centered care continues to enhance the adoption of drug eluting balloons in North America.

Europe is another significant region in the drug eluting balloons market, poised for steady growth due to the rising prevalence of chronic conditions such as coronary artery disease and peripheral artery disease. The European market is expected to witness a CAGR of approximately 5.5% from 2025 to 2035. Countries such as Germany, France, and the UK are leading contributors to the market, driven by robust healthcare systems and ongoing investments in medical technologies. The growing number of clinical studies and trials in Europe further supports the adoption of drug eluting balloons. Additionally, increasing awareness among healthcare providers regarding the benefits of these devices is anticipated to contribute to market growth across the region.

Opportunities

The Drug Eluting Balloons Market presents numerous opportunities for growth, particularly in emerging markets where healthcare infrastructure is rapidly developing. Countries in Asia Pacific and Latin America are witnessing significant improvements in their healthcare systems, leading to an increase in the demand for advanced medical technologies. The rising prevalence of chronic diseases, coupled with the growing elderly population in these regions, provides a fertile ground for drug eluting balloons. Manufacturers can capitalize on this trend by establishing partnerships with local healthcare providers and investing in regional distribution networks. Furthermore, the increasing investments in healthcare technology and innovations in drug delivery systems are likely to create new avenues for market expansion in these territories.

Another promising opportunity lies in the ongoing advancements in drug eluting balloon technology itself. Continuous research and development efforts aimed at improving the efficacy and safety profiles of these devices can lead to the introduction of next-generation products that cater to specific patient needs. Innovations such as biodegradable drug eluting balloons and those with enhanced drug release mechanisms can significantly alter treatment paradigms. Additionally, the integration of digital health technologies for better patient monitoring and personalized treatment plans can enhance the overall effectiveness of drug eluting balloon therapies. By focusing on these technological advancements, manufacturers can position themselves to capture higher market shares and meet the evolving demands of healthcare providers and patients alike.

Threats

While the Drug Eluting Balloons Market is on an upward trajectory, several threats could impede its growth. One significant concern is the increasing competition from alternative therapies and treatment modalities. Other vascular interventions, such as bare metal stents and conventional balloon angioplasty, continue to pose a challenge, especially in cost-sensitive markets. Additionally, the emergence of new technologies and treatment methodologies may divert attention and resources away from drug eluting balloons. As healthcare providers evaluate different treatment options, any negative clinical outcomes associated with DEBs could also impact their adoption and perceived value. Manufacturers must remain vigilant and proactive in addressing these competitive threats to maintain their market positions.

Moreover, regulatory challenges and stringent approval processes can restrict the rapid introduction of new products into the market. The complexity of clinical trials, coupled with the need for extensive safety and efficacy data, can lead to delays in product launches. Additionally, variations in regulatory requirements across different countries can complicate global market strategies for manufacturers. To mitigate these risks, companies must invest in robust clinical research and establish strong relationships with regulatory agencies. By doing so, they can navigate the regulatory landscape more effectively and minimize potential setbacks related to product approvals. Furthermore, addressing any potential safety concerns promptly and transparently will be crucial to sustaining trust and confidence in drug eluting balloon technologies.

Competitor Outlook

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Cook Medical
• Johnson & Johnson
• B. Braun Melsungen AG
• Terumo Corporation
• Cardinal Health
• Spectranetics Corporation
• Asahi Intecc Co., Ltd.
• Merit Medical Systems, Inc.
• AngioDynamics, Inc.
• EndoQuest Robotics, Inc.
• Inari Medical, Inc.
• Stratus Medical, LLC

The competitive landscape of the Drug Eluting Balloons Market is characterized by a mix of established players and emerging companies, all striving to gain market share through innovation and strategic positioning. Leading companies such as Medtronic and Boston Scientific are leveraging their extensive research and development capabilities to introduce advanced drug eluting balloon technologies. These companies focus not only on improving the effectiveness of their products but also on enhancing safety profiles to address any concerns regarding complications associated with balloon angioplasty. The ongoing competition encourages rapid advancements, ensuring that healthcare providers have access to cutting-edge treatment options that cater to the unique needs of patients suffering from vascular diseases.

In addition to large corporations, several smaller companies are entering the market with innovative solutions that focus on niche applications of drug eluting balloons. These emerging players are often more agile, allowing them to adapt quickly to changing market demands and regulatory environments. Collaborations between established firms and startups can lead to synergistic partnerships, fostering innovation and expanding product portfolios. The emphasis on personalized medicine and targeted therapies is motivating companies to explore new drug formulations and delivery mechanisms to enhance the therapeutic efficacy of drug eluting balloons. The competitive environment is expected to intensify as companies vie for prominence in this dynamic and rapidly evolving market.

Several key players are making significant strides in the Drug Eluting Balloons Market, including Abbott Laboratories and B. Braun Melsungen AG. Abbott has been at the forefront of innovation, continuously investing in research to develop advanced drug eluting balloon technologies. The company’s commitment to improving patient outcomes through effective and safe interventions has positioned it as a leader in the market. Similarly, B. Braun Melsungen AG has been recognized for its comprehensive range of vascular devices, including drug eluting balloons that cater to diverse medical applications. The company's focus on quality and safety has garnered it a strong reputation among healthcare professionals, facilitating its growth in this competitive landscape. As these companies continue to innovate and adapt to the evolving healthcare environment, their influence on the drug eluting balloons market will likely remain significant.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Cardinal Health
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Johnson & Johnson
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Terumo Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AngioDynamics, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Inari Medical, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Stratus Medical, LLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 B. Braun Melsungen AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Asahi Intecc Co., Ltd.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 EndoQuest Robotics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Spectranetics Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Merit Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Drug Eluting Balloons Market, By Drug Type
    • 6.1.1 Paclitaxel-Coated Balloons
    • 6.1.2 Sirolimus-Coated Balloons
    • 6.1.3 Other Drug Types
  • 6.2 Drug Eluting Balloons Market, By Application
    • 6.2.1 Coronary Artery Disease
    • 6.2.2 Peripheral Artery Disease
    • 6.2.3 Urological Diseases
    • 6.2.4 Neurological Diseases
    • 6.2.5 Others
  • 6.3 Drug Eluting Balloons Market, By Product Type
    • 6.3.1 Coronary Drug Eluting Balloons
    • 6.3.2 Peripheral Drug Eluting Balloons
    • 6.3.3 Urology Drug Eluting Balloons
    • 6.3.4 Neurology Drug Eluting Balloons
    • 6.3.5 Others
  • 6.4 Drug Eluting Balloons Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Drug Eluting Balloons Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Drug Eluting Balloons market is categorized based on

By Product Type

• Coronary Drug Eluting Balloons
• Peripheral Drug Eluting Balloons
• Urology Drug Eluting Balloons
• Neurology Drug Eluting Balloons
• Others

By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Urological Diseases
• Neurological Diseases
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Drug Type

• Paclitaxel-Coated Balloons
• Sirolimus-Coated Balloons
• Other Drug Types

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Cook Medical
• Johnson & Johnson
• B. Braun Melsungen AG
• Terumo Corporation
• Cardinal Health
• Spectranetics Corporation
• Asahi Intecc Co., Ltd.
• Merit Medical Systems, Inc.
• AngioDynamics, Inc.
• EndoQuest Robotics, Inc.
• Inari Medical, Inc.
• Stratus Medical, LLC